Evaluation of patients with acute pancreatitis associated with SARS-CoV-2 (COVID-19); The importance of lipase/lymphocyte ratio in predicting mortality

Bratisl Lek Listy. 2022;123(6):428-434. doi: 10.4149/BLL_2022_066.

Abstract

Background: SARS-CoV-2 is the cause of a pandemic with high mortality. In the present study, the effects of the lipase/lymphocyte ratio on mortality were investigated in cases diagnosed with Covid-19 and acute pancreatitis.

Methods: A total of 21 patients who were diagnosed with Covid-19 and acute pancreatitis, 34 patients who were not diagnosed with COVID-19 but diagnosed with acute pancreatitis, and 55 healthy control groups were divided into 3 groups and included in the study retrospectively. The patients who had positive RT-PCR (real‑time polymerized chain reaction) test results were included in the study. Complete blood count and biochemical values ​​of the patients were compared with those of the control group.

Results: When the data of the cases diagnosed with COVID-19 and acute pancreatitis were examined retrospectively, the amylase, lipase, lipase/lymphocyte ratio, and D-dimer levels were found to be significantly higher than in the control group (p < 0.01). In the ROC analysis, the amylase, lipase, and lipase/lymphocyte ratio had a high AUC (area under the curve) value (0.993 / 0.949 / 0.978, respectively).

Conclusion: The lipase/lymphocyte ratio can be used in cases diagnosed with Covid-19 and acute pancreatitis to predict mortality (Tab. 3, Fig. 3, Ref. 23).

Keywords: COVID-19; acute pancreatitis lipase/lymphocyte ratio..

MeSH terms

  • Acute Disease
  • Amylases
  • COVID-19* / complications
  • Humans
  • Lipase
  • Lymphocytes
  • Pancreatitis* / complications
  • Pancreatitis* / diagnosis
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Lipase
  • Amylases